| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Human cytomegalovirus (HCMV) protein kinase UL97. Maribavir inhibits UL97, which is essential for viral DNA replication and the production of infectious viral particles. This deuterated internal standard has no independent antiviral activity.
|
|---|---|
| ln Vitro |
Maribavir‑d6 TFA has no independent in vitro antiviral activity; it is an internal standard. The parent compound Maribavir is an orally active antiviral agent that inhibits CMV DNA replication by inhibiting protein kinase UL97. It has demonstrated potent activity against both wild‑type and drug‑resistant CMV strains.
|
| ln Vivo |
Maribavir‑d6 TFA has no independent in vivo activity. The parent compound Maribavir is an orally active antiviral approved for the treatment of post‑transplant CMV infection/disease that is refractory to other therapies. In clinical studies, Maribavir demonstrated efficacy in reducing CMV viral load and improving symptoms in transplant patients.
|
| Enzyme Assay |
General cell‑free protocol for using Maribavir‑d6 TFA as an internal standard: A fixed concentration of Maribavir‑d6 TFA (e.g., 50‑100 ng/mL) is added to plasma, serum, or tissue homogenate samples. Samples are processed by protein precipitation with acetonitrile or by SPE. The extract is analyzed by LC‑MS/MS in positive electrospray ionization mode. The m/z transitions for Maribavir and Maribavir‑d6 are monitored. The peak area ratio of analyte to internal standard is used to calculate the concentration.
|
| ADME/Pharmacokinetics |
General PK protocol for quantifying Maribavir using its deuterated internal standard: Plasma samples from Maribavir‑treated patients or animals are collected at various time points post‑dose. A fixed concentration of Maribavir‑d6 TFA is added to each sample. After protein precipitation, the supernatant is analyzed by LC‑MS/MS. The plasma concentration of Maribavir is calculated from the calibration curve. PK parameters (Cmax, Tmax, AUC, t1/2, clearance, volume of distribution, oral bioavailability) are determined.
|
| References | |
| Additional Infomation |
Maribavir‑d6 TFA has a molecular formula of C17H14D6Cl2F3N3O6 and a molecular weight of 496.30 g/mol. It is a deuterium‑labeled form of Maribavir (HY‑16305). The parent drug Maribavir is approved (Livtencity™) for the treatment of post‑transplant CMV infection/disease refractory to other therapies. It is an orally active antiviral agent that inhibits the CMV UL97 protein kinase, a novel mechanism of action distinct from DNA polymerase inhibitors like ganciclovir. The compound is stored at 4degC, sealed, away from moisture.
|
| Molecular Formula |
C17H14D6CL2F3N3O6
|
|---|---|
| Molecular Weight |
496.30
|
| Appearance |
Solid powder
|
| Synonyms |
1263W94-d6 TFA; BW1263W94-d6 TFA; GW257406X-d6 TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0149 mL | 10.0746 mL | 20.1491 mL | |
| 5 mM | 0.4030 mL | 2.0149 mL | 4.0298 mL | |
| 10 mM | 0.2015 mL | 1.0075 mL | 2.0149 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
